<?xml version="1.0" encoding="UTF-8"?>
<p id="p0210">Ribavirin is a guanine derivative approved for treating respiratory syncytial virus (RSV) and hepatitis C virus (HCV) infections, which also showed positive results in patients with SARS and MERS, but its side effects such as anemia may be severe at high doses 
 <xref rid="b0355" ref-type="bibr">[71]</xref>. Besides, its potency against SARS-CoV-2 is unknown 
 <xref rid="b0360" ref-type="bibr">[72]</xref>, 
 <xref rid="b0365" ref-type="bibr">[73]</xref>. One in-silico study revealed the potential ability of Sofosbuvir, Ribavirin, and Remdesevir to inhibit SARS-CoV-2 polymerase 
 <xref rid="b0370" ref-type="bibr">[74]</xref>. However, another study, mentioned above, ruled it out as an effective therapy for COVID-19. So, it is not yet clear whether it is effective against COVID-19 or not, and more investigation is needed.
</p>
